352 related articles for article (PubMed ID: 25429856)
1. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
Lee JW; Ryu JY; Yoon G; Jeon HK; Cho YJ; Choi JJ; Song SY; Do IG; Lee YY; Kim TJ; Choi CH; Kim BG; Bae DS
Int J Cancer; 2015 Jul; 137(1):221-9. PubMed ID: 25429856
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
Lee YY; Jeon HK; Hong JE; Cho YJ; Ryu JY; Choi JJ; Lee SH; Yoon G; Kim WY; Do IG; Kim MK; Kim TJ; Choi CH; Lee JW; Bae DS; Kim BG
Oncotarget; 2015 Oct; 6(33):35040-50. PubMed ID: 26418900
[TBL] [Abstract][Full Text] [Related]
3. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.
Pchejetski D; Bohler T; Brizuela L; Sauer L; Doumerc N; Golzio M; Salunkhe V; Teissié J; Malavaud B; Waxman J; Cuvillier O
Cancer Res; 2010 Nov; 70(21):8651-61. PubMed ID: 20959468
[TBL] [Abstract][Full Text] [Related]
4. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells.
Lim KG; Tonelli F; Li Z; Lu X; Bittman R; Pyne S; Pyne NJ
J Biol Chem; 2011 May; 286(21):18633-40. PubMed ID: 21464128
[TBL] [Abstract][Full Text] [Related]
5. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
6. Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma.
Han HD; Cho YJ; Cho SK; Byeon Y; Jeon HN; Kim HS; Kim BG; Bae DS; Lopez-Berestein G; Sood AK; Shin BC; Park YM; Lee JW
Mol Cancer Ther; 2016 Apr; 15(4):618-27. PubMed ID: 26861249
[TBL] [Abstract][Full Text] [Related]
7. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells.
Nagaoka Y; Otsuki K; Fujita T; Uesato S
Biol Pharm Bull; 2008 Jun; 31(6):1177-81. PubMed ID: 18520051
[TBL] [Abstract][Full Text] [Related]
8. Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.
Zhang L; Zhou D; Guan W; Ren W; Sun W; Shi J; Lin Q; Zhang J; Qiao T; Ye Y; Wu Y; Zhang Y; Zuo X; Connor KL; Xu G
Cell Death Dis; 2017 Dec; 8(12):3214. PubMed ID: 29238081
[TBL] [Abstract][Full Text] [Related]
9. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS
Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934
[TBL] [Abstract][Full Text] [Related]
10. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract][Full Text] [Related]
11. FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway.
Li MH; Hla T; Ferrer F
Pediatr Blood Cancer; 2013 Sep; 60(9):1418-23. PubMed ID: 23704073
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.
Li W; Li J; Wang Y; Zhang K; Li N; Tian Z; Ni B; Wang H; Ruan Z
Oncotarget; 2016 Dec; 7(49):80586-80598. PubMed ID: 27811359
[TBL] [Abstract][Full Text] [Related]
14. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells.
Ali JL; Lagasse BJ; Minuk AJ; Love AJ; Moraya AI; Lam L; Arthur G; Gibson SB; Morrison LC; Werbowetski-Ogilvie TE; Fu Y; Nachtigal MW
Int J Cancer; 2015 Mar; 136(5):E455-69. PubMed ID: 25227893
[TBL] [Abstract][Full Text] [Related]
15. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.
Tonelli F; Lim KG; Loveridge C; Long J; Pitson SM; Tigyi G; Bittman R; Pyne S; Pyne NJ
Cell Signal; 2010 Oct; 22(10):1536-42. PubMed ID: 20570726
[TBL] [Abstract][Full Text] [Related]
16. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
Saed GM; Fletcher NM; Diamond MP; Morris RT; Gomez-Lopez N; Memaj I
Gynecol Oncol; 2018 Mar; 148(3):567-575. PubMed ID: 29329880
[TBL] [Abstract][Full Text] [Related]
17. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
18. Picropodophyllin inhibits epithelial ovarian cancer cells in vitro and in vivo.
Lu X; Wang L; Mei J; Wang X; Zhu X; Zhang Q; Lv J
Biochem Biophys Res Commun; 2013 Jun; 435(3):385-90. PubMed ID: 23665331
[TBL] [Abstract][Full Text] [Related]
19. Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart.
Vessey DA; Kelley M; Zhang J; Li L; Tao R; Karliner JS
J Biochem Mol Toxicol; 2007; 21(5):273-9. PubMed ID: 17912702
[TBL] [Abstract][Full Text] [Related]
20. Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer.
Paik ES; Kim TH; Cho YJ; Ryu J; Choi JJ; Lee YY; Kim TJ; Choi CH; Kim WY; Sa JK; Lee JK; Kim BG; Bae DS; Han HD; Ahn HJ; Lee JW
Sci Rep; 2020 Mar; 10(1):4904. PubMed ID: 32184452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
